Comparative Pharmacology
Head-to-head clinical analysis: HALOPERIDOL LACTATE versus TARACTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOPERIDOL LACTATE versus TARACTAN.
HALOPERIDOL LACTATE vs TARACTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Haloperidol lactate is a typical antipsychotic that exerts its effects primarily by blocking dopamine D2 receptors in the brain, particularly in the mesolimbic and mesocortical pathways. It also has antagonistic activity at alpha-1 adrenergic receptors and limited affinity for serotonin receptors.
Thioxanthene antipsychotic; blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic system; also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
2-5 mg intramuscularly or intravenously every 4-8 hours for acute agitation. Maximum 20 mg/day.
Oral: 25-50 mg three times daily, increased as needed to 400-600 mg/day. IM: 12.5-25 mg every 6-8 hours.
None Documented
None Documented
14–26 hours (terminal elimination half-life); may be prolonged in hepatic impairment or with repeated dosing due to accumulation.
Terminal elimination half-life is approximately 20-40 hours (mean 30 hours). Steady-state reached in 5-7 days.
Renal (approximately 40% as metabolites, <1% as unchanged drug); fecal (approximately 15%); remainder metabolized with unknown fate.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Metabolites eliminated renally (30%) and fecally (70%).
Category A/B
Category C
Typical Antipsychotic
Typical Antipsychotic